Bristol-Myers Squibb (NYSE:BMY) Target Lowered by Morgan Stanley to $66.00

Bristol-Myers Squibb stock has undergone multiple analysts rating changes in the recent past.  stock Target Lowered by Morgan Stanley on 10/12/2021. In a note to investors, the firm issued a new target price of $66.00. The analysts previously had $71.00 target price. Morgan Stanley’s price target would indicate a potential upside of 14.94% from the stock’s previous close.

Shares of traded on monday, reaching $57.54. 1376998 shares of the stock traded hands, compared to its average volume of 10991582. On monday, Shares of closed at $57.54. The firm’s 50 day moving average is $63.99 and its 200 day moving average is $64.16.  has a 12 month low of $56.75 and a 12 month high of $69.75. While on yearly highs and lows, today has traded high as $57.69 and has touched $56.97 on the downward trend.

Earnings and What to expect: 

Bristol-Myers Squibb last released its earnings results on July 27th, 2021. The biopharmaceutical company reported $1.93 earnings per share for the quarter, topping analysts’ consensus estimates of $1.89 by $0.04. The company had revenue of $11.70 billion for the quarter, compared to analyst estimates of $11.24 billion. Bristol-Myers Squibb has generated $6.44 earnings per share over the last year (($2.27) diluted earnings per share). Earnings for Bristol-Myers Squibb are expected to grow by 8.31% in the coming year, from $7.46 to $8.08 per share. Bristol-Myers Squibb has confirmed that its next quarterly earnings report will be published on Wednesday, October 27th, 2021. Bristol-Myers Squibb will be holding an earnings conference call on Wednesday, October 27th at 8:00 AM Eastern. Interested parties can or dial in at 719-457-0820 with passcode “8911662”.

Earnings for Bristol-Myers Squibb are expected to grow by 8.31% in the coming year, from $7.46 to $8.08 per share. The P/E ratio of Bristol-Myers Squibb is -25.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Bristol-Myers Squibb is -25.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Bristol-Myers Squibb has a PEG Ratio of 1.20. PEG Ratios above 1 indicate that a company could be overvalued. Bristol-Myers Squibb has a P/B Ratio of 3.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

(NYSE:BMY) Moving Average Technical Analysis

5 day Moving Average is $$58.11 And 5 day price change is -$1.47 (-2.49%)  with average volume for 5 day average is 12,215,470. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $59.70 and 20 day price change is -$4.43 (-7.13%) and average 20 day moving volume is 11,626,152. 50 day moving average is $63.99  and 50 day price change is -$10.34 ( -15.20%)  and with average volume for 50 days is : 9,254,737. 200 day moving average is $64.16  and 200 day price change is -$3.47 (-5.67%)  and with average volume for 200 days is : 10,562,779.

Other owners latest trading in Bristol-Myers Squibb :

  • On 10/12/2021 shares held by First Hawaiian Bank were 53,073 which equates to market value of $3.14M and appx 0.10% owners of Bristol-Myers Squibb
  • On 10/8/2021 shares held by HBW Advisory Services LLC were 7,428 which equates to market value of $0.44M and appx 0.10% owners of Bristol-Myers Squibb
  • On 10/8/2021 shares held by Vigilant Capital Management LLC were 1,921 which equates to market value of $0.11M and appx 0.00% owners of Bristol-Myers Squibb
  • In total Institutional ownership equates to Institutional Ownership Percentage: 72.10% for Bristol-Myers Squibb

See More Analyst Rating at: RATING